US pharma major Eli Lilly to establish second Indian GCC in Hyderabad

Company plans to employ 1,000-1,500 skilled professionals; GCC to focus on automation, AI

US-based pharma major Eli Lilly and Company will set up a new global capability centre (GCC) in Hyderabad, the second such facility in India which the firm said will strengthen its digital strategy and service delivery and employ over 1,000 highly-skilled professionals.

 

In the announcement, made on Wednesday, the company said that the new GCC -- Lilly Capability Centre India (LCCI) -- is expected to be operational by mid-2025 and recruitment for the new site is underway.

 

The US major opened its first GCC in Bengaluru in 2016.

 

While the company did not respond to queries regarding investment in the Hyderabad GCC, a spokesperson said that it is expected to be significant. 

 

The company plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers and data scientists. Lilly currently employs over 3,000 people at its Bengaluru centre.

 

The Hyderabad GCC will initially focus on expanding the company’s capabilities in automation, artificial intelligence, software product engineering and cloud computing to deliver advanced technology solutions that meet the evolving needs of Lilly’s business worldwide.

 

A spokesperson for the pharma company said that the centre would aim to improve service delivery capabilities across its global operations.

 

Commenting on the launch of the centre, Manish Arora, managing director, Lilly Capability Centre India (LCCI) Hyderabad said that the centre will enhance Lilly’s technical capabilities, enabling it to better meet growing business demands, fully leverage technology in operations, and further expand its presence in India.

 

“Establishing this new centre in India is part of our global strategy to invest in growth markets. Our Bengaluru-based LCCI has been highly successful, and Hyderabad provides the ideal combination of infrastructure, talent, and a thriving ecosystem to support our expansion,” a spokesperson for Eli Lilly and Company added.